🚀 VC round data is live in beta, check it out!
Innovita Biological Tech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Innovita Biological Tech and similar public comparables like RaySearch Labs, Lumexa Imaging, Diagnósticos da América, Lunit and more.
Innovita Biological Tech Overview
About Innovita Biological Tech
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
Founded
2006
HQ
Employees
547
Website
Financials (FY)
EV
$601M
Innovita Biological Tech Financials
Innovita Biological Tech reported last fiscal year revenue of $91M and EBITDA of $44M.
In the same fiscal year, Innovita Biological Tech generated $73M in gross profit, $44M in EBITDA, and $36M in net income.
Revenue (LTM)
Innovita Biological Tech P&L
In the most recent fiscal year, Innovita Biological Tech reported revenue of $91M and EBITDA of $44M.
Innovita Biological Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $91M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $73M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 80% | XXX | XXX | XXX |
| EBITDA | — | XXX | $44M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 42% | XXX | XXX | XXX |
| Net Profit | — | XXX | $36M | XXX | XXX | XXX |
| Net Margin | — | XXX | 40% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Innovita Biological Tech Stock Performance
Innovita Biological Tech has current market cap of $871M, and enterprise value of $601M.
Market Cap Evolution
Innovita Biological Tech's stock price is $6.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $601M | $871M | 0.0% | XXX | XXX | XXX | $0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInnovita Biological Tech Valuation Multiples
Innovita Biological Tech trades at 6.6x EV/Revenue multiple, and 13.7x EV/EBITDA.
EV / Revenue (LTM)
Innovita Biological Tech Financial Valuation Multiples
As of April 20, 2026, Innovita Biological Tech has market cap of $871M and EV of $601M.
Equity research analysts estimate Innovita Biological Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Innovita Biological Tech has a P/E ratio of 24.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $871M | XXX | $871M | XXX | XXX | XXX |
| EV (current) | $601M | XXX | $601M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 15.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.2x | XXX | XXX | XXX |
| P/E | — | XXX | 24.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 15.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Innovita Biological Tech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Innovita Biological Tech Margins & Growth Rates
Innovita Biological Tech's revenue in the last fiscal year grew by 30%.
Innovita Biological Tech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Innovita Biological Tech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Innovita Biological Tech Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Innovita Biological Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| RaySearch Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Lumexa Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnósticos da América | XXX | XXX | XXX | XXX | XXX | XXX |
| Lunit | XXX | XXX | XXX | XXX | XXX | XXX |
| Castle Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innovita Biological Tech M&A Activity
Innovita Biological Tech acquired XXX companies to date.
Last acquisition by Innovita Biological Tech was on XXXXXXXX, XXXXX. Innovita Biological Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Innovita Biological Tech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInnovita Biological Tech Investment Activity
Innovita Biological Tech invested in XXX companies to date.
Innovita Biological Tech made its latest investment on XXXXXXXX, XXXXX. Innovita Biological Tech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Innovita Biological Tech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Innovita Biological Tech
| When was Innovita Biological Tech founded? | Innovita Biological Tech was founded in 2006. |
| Where is Innovita Biological Tech headquartered? | Innovita Biological Tech is headquartered in China. |
| How many employees does Innovita Biological Tech have? | As of today, Innovita Biological Tech has over 547 employees. |
| Is Innovita Biological Tech publicly listed? | Yes, Innovita Biological Tech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Innovita Biological Tech? | Innovita Biological Tech trades under 688253 ticker. |
| When did Innovita Biological Tech go public? | Innovita Biological Tech went public in 2022. |
| Who are competitors of Innovita Biological Tech? | Innovita Biological Tech main competitors are RaySearch Labs, Lumexa Imaging, Diagnósticos da América, Lunit. |
| What is the current market cap of Innovita Biological Tech? | Innovita Biological Tech's current market cap is $871M. |
| What is the current revenue of Innovita Biological Tech? | Innovita Biological Tech's last fiscal year revenue is $91M. |
| What is the current EV/Revenue multiple of Innovita Biological Tech? | Current revenue multiple of Innovita Biological Tech is 6.6x. |
| Is Innovita Biological Tech profitable? | No, Innovita Biological Tech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.